1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Iran Pharmaceuticals and Healthcare Report Q3 2016

Iran Pharmaceuticals and Healthcare Report Q3 2016

  • July 2016
  • -
  • Business Monitor International
  • -
  • 98 pages

Includes 3 FREE quarterly updates

BMI View: The Iranian government is looking to attract greater direct investment by leveraging thegrowing interest of multinational pharmaceutical companies interested in exploring the high-growthpotential of Iran's pharmaceutical market in the post-sanctions period. However, given underlyingoperating challenges within Iran's pharmaceutical market, the arrival of multinational drugmakers will bea gradual process, rather than an immediate boom.Headline Expenditure Projections

- Pharmaceuticals: IRR69.55trn (USD1.93bn) in 2015 to IRR79.85trn (USD2.00bn) in 2016; +14.8% inlocal currency terms and +3.3% in US dollar terms. Forecast upgraded from previous quarter.

- Healthcare: IRR800.60trn (USD22.24bn) in 2015 to IRR898.48trn (USD22.46bn) in 2016; +12.2% inlocal currency terms and +1.0% in US dollar terms. Forecast downgraded from previous quarter.

Table Of Contents

Iran Pharmaceuticals and Healthcare Report Q3 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Iran 2014-2020) 7
SWOT 9
Industry Forecast 12
Pharmaceutical Market Forecast 12
Table: Pharmaceutical Sales, Historical Data And Forecasts (Iran 2012-2020) 15
Healthcare Market Forecast 16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Iran 2012-2020) 18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Iran 2012-2020) 19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Iran 2012-2020) 20
Prescription Drug Market Forecast 21
Patented Drug Market Forecast 23
Generic Drug Market Forecast 24
OTC Market Forecast 25
Pharmaceutical Trade Forecast 26
Table: Pharmaceutical Trade Data And Forecasts (Iran 2014-2020) 29
Table: Pharmaceutical Trade Data And Forecasts local currency (Iran 2014-2020) 29
Industry Risk/Reward Index 30
Middle East and Africa Risk/Reward Index - Q3 2016 30
Iran Risk/Reward Index 38
Rewards 38
Risks 39
Regulatory Review 40
Intellectual Property Issues 42
Pricing and Reimbursement Regime 44
Market Overview 46
Healthcare Sector 47
Table: Healthcare Resources (Iran 2010-2015) 50
Table: Healthcare Personnel (Iran 2010-2015) 50
Table: Healthcare Activity (Iran 2010-2015) 51
Research and Development 54
Clinical Trials 58
Epidemiology 58
Competitive Landscape 62
Research-Based Industry 62
Table: Multinational Company Activity 65
Generic Drugmakers 66
Table: Leading Drug Manufacturers, Iran - To March 2009 66
Pharmaceutical Distribution 69
Table: Leading Distributors, Iranian - Year To March 20 2008 70
Pharmaceutical Retail Sector 71
Table: Tehran Stock Exchange - Listed Pharmaceutical Companies As Of November 2015 71
Company Profile 73
Caspian Tamin Pharmaceutical Company 73
Darou Pakhsh 76
Exir Pharmaceuticals 79
Pars Darou 82
Zahravi Pharmaceutical Company 84
Demographic Forecast 87
Table: Population Headline Indicators (Iran 1990-2025) 88
Table: Key Population Ratios (Iran 1990-2025) 88
Table: Urban/Rural Population and Life Expectancy (Iran 1990-2025) 89
Table: Population By Age Group (Iran 1990-2025) 89
Table: Population By Age Group % (Iran 1990-2025) 90
Glossary 92
Methodology 94
Pharmaceutical Expenditure Forecast Model 94
Healthcare Expenditure Forecast Model 94
Notes On Methodology 95
Risk/Reward Index Methodology 96
Index Overview 97
Table: Pharmaceutical Risk/Reward Index Indicators 97
Indicator Weightings 98

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.